Integrated Insurance Design in the Presence of Multiple Medical Technologies
Author
Abstract
(This abstract was borrowed from another version of this item.)
Suggested Citation
Note: DOI: 10.1257/aer.97.2.427
Download full text from publisher
As the access to this document is restricted, you may want to look for a different version below or search for a different version of it.
Other versions of this item:
- Dana Goldman & Tomas Philipson, 2007. "Integrated Insurance Design in the Presence of Multiple Medical Technologies," NBER Working Papers 12870, National Bureau of Economic Research, Inc.
References listed on IDEAS
- Martin Gaynor & Jian Li & William B. Vogt, 2006.
"Is Drug Coverage a Free Lunch? Cross-Price Elasticities and the Design of Prescription Drug Benefits,"
NBER Working Papers
12758, National Bureau of Economic Research, Inc.
- Martin Gaynor & Jian Li & William B. Vogt, 2006. "Is Drug Coverage a Free Lunch? Cross-Price Elasticities and the Design of Prescription Drug Benefits," The Centre for Market and Public Organisation 07/166, The Centre for Market and Public Organisation, University of Bristol, UK.
- Pauly, Mark V. & Held, Philip J, 1990. "Benign moral hazard and the cost-effectiveness analysis of insurance coverage," Journal of Health Economics, Elsevier, vol. 9(4), pages 447-461, December.
- Lichtenberg, Frank R, 1996. "Do (More and Better) Drugs Keep People Out of Hospitals?," American Economic Review, American Economic Association, vol. 86(2), pages 384-388, May.
Most related items
These are the items that most often cite the same works as this one and are cited by the same works as this one.- Toole, Andrew A. & Czarnitzki, Dirk, 2007. "Life Scientist Mobility from Academe to Industry: Does Academic Entrepreneurship Induce a Costly ?Brain Drain? on the Not-for-Profit Research Sector?," ZEW Discussion Papers 07-072, ZEW - Leibniz Centre for European Economic Research.
- Frank R. Lichtenberg, 2001.
"The Allocation of Publicly Funded Biomedical Research,"
NBER Chapters, in: Medical Care Output and Productivity,
National Bureau of Economic Research, Inc.
- Frank Lichtenberg, 1997. "The Allocation of Publicly-Funded Biomedical Research," CESifo Working Paper Series 140, CESifo.
- Frank R. Lichtenberg, 1998. "The Allocation of Publicly-Funded Biomedical Research," NBER Working Papers 6601, National Bureau of Economic Research, Inc.
- Nebibe Varol & Joan Costa-i-Font & Alistair McGuire, 2011. "Explaining Early Adoption on New Medicines: Regulation, Innovation and Scale," CESifo Working Paper Series 3459, CESifo.
- James W. Hughes & Michael J. Moore & Edward A. Snyder, 2002.
""Napsterizing" Pharmaceuticals: Access, Innovation, and Consumer Welfare,"
NBER Working Papers
9229, National Bureau of Economic Research, Inc.
- James W Hughes & Michael J Moore & Edward A Snyder, 2003. "Napsterizing Pharmaceuticals: Access, Innovation and Consumer Welfare," Levine's Working Paper Archive 618897000000000555, David K. Levine.
- Adriana Lleras-Muney & Frank R. Lichtenberg, 2002. "The Effect of Education on Medical Technology Adoption: Are the More Educated More Likely to Use New Drugs," NBER Working Papers 9185, National Bureau of Economic Research, Inc.
- Frank Lichtenberg, 2006. "The Effect of Using Newer Drugs on Admissions of Elderly Americans to Hospitals and Nursing Homes: State-level Evidence from 1997 to 2003," PharmacoEconomics, Springer, vol. 24(3), pages 5-25, December.
- Nebibe Varol & Joan Costa-Font & Alistair McGuire, 2012.
"Do International Launch Strategies of Pharmaceutical Corporations Respond to Changes in the Regulatory Environment?,"
Chapters, in: Alistair McGuire & Joan Costa-Font (ed.), The LSE Companion to Health Policy, chapter 12,
Edward Elgar Publishing.
- Varol, Nebibe & Costa-i-Font, Joan & McGuire, Alistair, 2010. "Do international launch strategies of pharmaceutical corporations respond to changes in the regulatory environment?," LSE Research Online Documents on Economics 29972, London School of Economics and Political Science, LSE Library.
- Frank R. Lichtenberg, 2002. "The Effect of Changes in Drug Utilization on Labor Supply and Per Capita Output," NBER Working Papers 9139, National Bureau of Economic Research, Inc.
- Claude Montmarquette & Stéphanie Boulenger & Joanne Castonguay, 2014. "Les risques liés à la création de PHARMA-QUEBEC," CIRANO Project Reports 2014rp-05, CIRANO.
- Marianne Simonsen & Lars Skipper & Niels Skipper, 2016.
"Price Sensitivity of Demand for Prescription Drugs: Exploiting a Regression Kink Design,"
Journal of Applied Econometrics, John Wiley & Sons, Ltd., vol. 31(2), pages 320-337, March.
- Marianne Simonsen & Lars Skipper & Niels Skipper, 2010. "Price Sensitivity of Demand for Prescription Drugs: Exploiting a Regression Kink Design," Economics Working Papers 2010-03, Department of Economics and Business Economics, Aarhus University.
- Simonsen, Marianne & Skipper, Lars & Skipper, Niels, 2010. "Price Sensitivity of Demand for Prescription Drugs: Exploiting a Regression Kink Design," Working Papers 10-1, University of Aarhus, Aarhus School of Business, Department of Economics.
- Joseph Eisenhauer, 2006. "Severity of illness and the welfare effects of moral hazard," International Journal of Health Economics and Management, Springer, vol. 6(4), pages 290-299, December.
- Giaccotto, Carmelo & Santerre, Rexford E & Vernon, John A, 2005. "Drug Prices and Research and Development Investment Behavior in the Pharmaceutical Industry," Journal of Law and Economics, University of Chicago Press, vol. 48(1), pages 195-214, April.
- Frank Lichtenberg, 2000.
"The Benefits and Costs of Newer Drugs: Evidence from the 1996 Medical Expenditure Panel Survey,"
CESifo Working Paper Series
404, CESifo.
- Frank R. Lichtenberg, 2001. "The Benefits and Costs of Newer Drugs: Evidence from the 1996 Medical Expenditure Panel Survey," NBER Working Papers 8147, National Bureau of Economic Research, Inc.
- Matear, Margaret & Dacin, Peter A., 2010. "Marketing and societal welfare: A multiple stakeholder approach," Journal of Business Research, Elsevier, vol. 63(11), pages 1173-1178, November.
- Di Novi, Cinzia & Leporatti, Lucia & Levaggi, Rosella & Montefiori, Marcello, 2022. "Adherence during COVID-19: The role of aging and socio-economics status in shaping drug utilization," Journal of Economic Behavior & Organization, Elsevier, vol. 204(C), pages 1-14.
- Duggan, Mark, 2005. "Do new prescription drugs pay for themselves?: The case of second-generation antipsychotics," Journal of Health Economics, Elsevier, vol. 24(1), pages 1-31, January.
- Dirk Czarnitzki & Katrin Hussinger & Cédric Schneider, 2011.
"Commercializing academic research: the quality of faculty patenting,"
Industrial and Corporate Change, Oxford University Press and the Associazione ICC, vol. 20(5), pages 1403-1437, October.
- Schneider, Cédric & Hussinger, Katrin & Czarnitzki, Dirk, 2008. "Commercializing Academic Research: The Quality of Faculty Patenting," ZEW Discussion Papers 08-069, ZEW - Leibniz Centre for European Economic Research.
- Czarnitzki, Dirk & Hussinger, Katrin & Schneider, Cedric, 2008. "Commercializing Academic Research: The Qaulity of Faculty Patenting," Working Papers 05-2008, Copenhagen Business School, Department of Economics.
- Laurie J. Bates & Kankana Mukherjee & Rexford E. Santerre, 2010. "Medical Insurance Coverage and Health Production Efficiency," Journal of Risk & Insurance, The American Risk and Insurance Association, vol. 77(1), pages 211-229, March.
- Abdülkadi̇r Ci̇van & Bülent Köksal, 2010.
"The effect of newer drugs on health spending: do they really increase the costs?,"
Health Economics, John Wiley & Sons, Ltd., vol. 19(5), pages 581-595, May.
- Civan, Abdülkadir & Koksal, Bulent, 2007. "The Effect of Newer Drugs on Health Spending: Do They Really Increase the Costs?," MPRA Paper 6846, University Library of Munich, Germany.
- Frank Lichtenberg, 2005.
"The Impact of New Drug Launches on Longevity: Evidence from Longitudinal, Disease-Level Data from 52 Countries, 1982–2001,"
International Journal of Health Economics and Management, Springer, vol. 5(1), pages 47-73, January.
- Frank R. Lichtenberg, 2003. "The impact of new drug launches on longevity: evidence from longitudinal disease-level data from 52 countries, 1982-2001," NBER Working Papers 9754, National Bureau of Economic Research, Inc.
More about this item
JEL classification:
- I1 - Health, Education, and Welfare - - Health
- I10 - Health, Education, and Welfare - - Health - - - General
Statistics
Access and download statisticsCorrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:aea:aecrev:v:97:y:2007:i:2:p:427-432. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Michael P. Albert (email available below). General contact details of provider: https://edirc.repec.org/data/aeaaaea.html .
Please note that corrections may take a couple of weeks to filter through the various RePEc services.